Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11380646 | 0.85 | SYK (0.58) | SYKSMN1; SMN2NPC1ALDH1A1TP53 | |
| SCHEMBL523765 | 0.82 | SYK (0.64) | SYK | |
| SCHEMBL4766383 | 0.82 | ADORA2A (0.46) | SYKSMN1; SMN2NPC1ALDH1A1TP53 | |
| SCHEMBL17210724 | 0.78 | PDGFRB (0.43) | SYKPDGFRBPDGFRAPGK1 | |
| SCHEMBL524226 | 0.77 | SYK (0.55) | SYKL3MBTL1 | |
| SCHEMBL2589917 | 0.77 | MAPK1 (0.55) | SYKSMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL3284282 | 0.74 | SYK (0.60) | SYKSMN1; SMN2NPC1TP53RAB9A | |
| SCHEMBL3280663 | 0.74 | SYK (0.71) | SYKNPC1ALDH1A1TP53MAPT | |
| SCHEMBL11370853 | 0.73 | SYK (0.62) | SYKSMN1; SMN2ALDH1A1ADORA2APDGFRB | |
| SCHEMBL10196451 | 0.72 | SYK (1.00) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| EP-2563788-B1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE-INFLAMMATORY DISEASES | KARUS THERAPEUTICS LTD (GB) | 2015-08-05 | — | — | EP | disclosed |
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
| CN-102985421-A | Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases | KARUS THERAPEUTICS LTD | 2013-03-20 | — | — | CN | disclosed |
| EP-2563788-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | Karus Therapeutics Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011135351-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | KARUS THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | PIK3R5, PIK3CA, NFKBIA | SYK 140/4885SMN1; SMN2 3274/4885NPC1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.